Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma
Pierina Navarria(IRCCS Humanitas Research Hospital), Marta Scorsetti(Humanitas University), Stefano Tomatis(IRCCS Humanitas Research Hospital), Vittorio Quagliuolo(Humanitas University), Antonella Fogliata(IRCCS Humanitas Research Hospital), Rita De Sanctis(Humanitas University), Andrea Marrari(IRCCS Humanitas Research Hospital), Giuseppe Roberto D’Agostino(Humanitas University), Luca Cozzi(IRCCS Humanitas Research Hospital), Umberto Cariboni(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Fiorenza De Rose, A.M. Ascolese(IRCCS Humanitas Research Hospital), Marco Alloisio(IRCCS Humanitas Research Hospital)
Cited by 98
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646